JPWO2020257573A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020257573A5 JPWO2020257573A5 JP2021575994A JP2021575994A JPWO2020257573A5 JP WO2020257573 A5 JPWO2020257573 A5 JP WO2020257573A5 JP 2021575994 A JP2021575994 A JP 2021575994A JP 2021575994 A JP2021575994 A JP 2021575994A JP WO2020257573 A5 JPWO2020257573 A5 JP WO2020257573A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- crystalline
- salt
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 239000013078 crystal Substances 0.000 claims 12
- 108010011485 Aspartame Proteins 0.000 claims 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims 6
- 229960003438 aspartame Drugs 0.000 claims 6
- 235000010357 aspartame Nutrition 0.000 claims 6
- 239000000605 aspartame Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 5
- 159000000007 calcium salts Chemical class 0.000 claims 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- 150000003863 ammonium salts Chemical class 0.000 claims 2
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical class NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- 150000004885 piperazines Chemical class 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864873P | 2019-06-21 | 2019-06-21 | |
| US62/864,873 | 2019-06-21 | ||
| PCT/US2020/038624 WO2020257573A1 (en) | 2019-06-21 | 2020-06-19 | Salt forms of bempedoic acid and methods for using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536979A JP2022536979A (ja) | 2022-08-22 |
| JPWO2020257573A5 true JPWO2020257573A5 (enExample) | 2023-06-16 |
Family
ID=71528020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575994A Withdrawn JP2022536979A (ja) | 2019-06-21 | 2020-06-19 | 塩形態のベンペド酸及びそれを使用する方法 |
| JP2021575993A Pending JP2022537049A (ja) | 2019-06-21 | 2020-06-19 | ベンペド酸の製造方法及びその組成物 |
| JP2024211105A Pending JP2025032197A (ja) | 2019-06-21 | 2024-12-04 | ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575993A Pending JP2022537049A (ja) | 2019-06-21 | 2020-06-19 | ベンペド酸の製造方法及びその組成物 |
| JP2024211105A Pending JP2025032197A (ja) | 2019-06-21 | 2024-12-04 | ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (10) | US12344578B2 (enExample) |
| EP (3) | EP3986859B1 (enExample) |
| JP (3) | JP2022536979A (enExample) |
| KR (3) | KR20250143358A (enExample) |
| CN (3) | CN112437765A (enExample) |
| AU (3) | AU2020296094B2 (enExample) |
| BR (2) | BR112021025928A2 (enExample) |
| CA (2) | CA3144372A1 (enExample) |
| ES (1) | ES3032779T3 (enExample) |
| HU (1) | HUE072061T2 (enExample) |
| IL (3) | IL288909A (enExample) |
| MX (2) | MX2021015935A (enExample) |
| WO (2) | WO2020257571A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12344578B2 (en) | 2019-06-21 | 2025-07-01 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
| CN114746389A (zh) | 2019-10-03 | 2022-07-12 | 斯索恩有限公司 | 贝派地酸的晶形 |
| EP4069668A1 (en) * | 2019-12-06 | 2022-10-12 | Synthon B.V. | Crystalline forms of sodium salt of bempedoic acid |
| CN111559961A (zh) * | 2020-05-26 | 2020-08-21 | 杭州科巢生物科技有限公司 | 一种贝派地酸晶型及其制备方法 |
| WO2021255180A1 (en) * | 2020-06-19 | 2021-12-23 | Synthon B.V. | Salts of bempedoic acid |
| CN112521282A (zh) * | 2020-12-02 | 2021-03-19 | 苏州汉德创宏生化科技有限公司 | 一种贝派地酸中间体及其合成方法 |
| WO2022149161A1 (en) * | 2021-01-05 | 2022-07-14 | Dr. Reddy's Laboratories Limited | Process for preparation of bempedoic acid and its intermediates |
| JP2024521354A (ja) | 2021-06-02 | 2024-05-31 | エスペリオン・セラピューティクス・インコーポレイテッド | ベンペド酸とトルバブタンを含む組成物及びそれらを用いた治療方法 |
| CN115504914B (zh) * | 2021-06-23 | 2024-05-07 | 武汉武药科技有限公司 | 一种贝派地酸中间体的制备方法 |
| CN114436837B (zh) * | 2021-12-27 | 2024-02-20 | 甘李药业股份有限公司 | 一种贝派地酸中间体的纯化方法 |
| WO2023187833A1 (en) * | 2022-03-30 | 2023-10-05 | Enaltec Labs Private Limited | A novel salt of bempedoic acid |
| WO2024151311A1 (en) | 2023-01-09 | 2024-07-18 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
| CN116589341A (zh) * | 2023-04-14 | 2023-08-15 | 苏州汉德创宏生化科技有限公司 | 一种抗高血酯药物中间体的制备方法 |
| WO2025196153A1 (en) | 2024-03-20 | 2025-09-25 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| WO2025196155A1 (en) | 2024-03-20 | 2025-09-25 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| WO2025196154A1 (en) | 2024-03-20 | 2025-09-25 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| WO2025238159A1 (en) | 2024-05-16 | 2025-11-20 | Astrazeneca Ab | Combination therapy comprising azd0780 and ezetimibe |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3152148A (en) | 1963-01-03 | 1964-10-06 | Dow Chemical Co | Preparation of comenic and pyromeconic acids |
| US3441605A (en) | 1965-02-17 | 1969-04-29 | Wallace & Tiernan Inc | Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation |
| GB1196598A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a Ketosebacic Acid |
| GB1196595A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a Lactone |
| GB1196597A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of an Oxido-Cyclodecene |
| GB1196594A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Improvements in and relating to the production of Sebacic Acid |
| FR1545224A (fr) | 1966-12-21 | 1968-11-08 | Geigy Ag J R | Procédé de préparation de l'acide sébacique |
| GB1196596A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a hydroxysebacic acid |
| US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| US4281200A (en) | 1979-08-30 | 1981-07-28 | The Dow Chemical Company | Catalytic process for converting oxazolidinones to their corresponding aminoalcohols |
| JPS5639033A (en) | 1979-09-04 | 1981-04-14 | Kao Corp | Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same |
| IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| IT1164254B (it) | 1983-05-30 | 1987-04-08 | Luso Farmaco Inst | 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione |
| JPS59232811A (ja) | 1983-06-16 | 1984-12-27 | Sumitomo Chem Co Ltd | 芳香族ポリアミドイミド樹脂成形体の製造方法 |
| JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
| DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| US4896344A (en) | 1984-10-15 | 1990-01-23 | Grady John K | X-ray video system |
| US4634119A (en) | 1985-07-11 | 1987-01-06 | Pesthy Paul K | Resilient exercise machine with body support platform |
| US4714762A (en) | 1986-10-31 | 1987-12-22 | Warner-Lambert Company | Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof |
| US5225439A (en) | 1987-01-28 | 1993-07-06 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US5428062A (en) | 1987-01-28 | 1995-06-27 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US4758880A (en) | 1987-03-27 | 1988-07-19 | The Grass Valley Group, Inc. | Video matte generator |
| JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Ｄｎａおよびその用途 |
| US5254589A (en) | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
| IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
| US5420339A (en) | 1993-11-22 | 1995-05-30 | Warner-Lambert Company | Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors |
| JP2937012B2 (ja) | 1994-04-08 | 1999-08-23 | 時久 増田 | 角筒包装袋の製造方法及び装置 |
| US5504073A (en) | 1994-07-01 | 1996-04-02 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| US5578639A (en) | 1994-07-01 | 1996-11-26 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| AU720853B2 (en) | 1995-11-02 | 2000-06-15 | Warner-Lambert Company | Method and pharmaceutical composition for regulating lipid concentration |
| JP4139448B2 (ja) | 1996-08-13 | 2008-08-27 | 信越化学工業株式会社 | α−ブロモ，ω−クロロアルカンの製造方法 |
| US5807846A (en) | 1996-11-14 | 1998-09-15 | Warner-Lambert Company | Phosphonamide ACAT inhibitors |
| IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
| US6093744A (en) | 1997-04-21 | 2000-07-25 | Warner-Lambert Company | N-acyl sulfamic acid esters useful as hypocholesterolemic agents |
| IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| WO1999026583A2 (en) | 1997-11-25 | 1999-06-03 | Warner-Lambert Company | Inhibtion of lipoprotein oxidation |
| CN1329359C (zh) | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
| JP2004531459A (ja) | 2000-10-11 | 2004-10-14 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用 |
| MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| CN1283610C (zh) | 2000-10-11 | 2006-11-08 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
| JP2004532799A (ja) | 2000-10-11 | 2004-10-28 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物 |
| US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US7053046B2 (en) | 2001-12-21 | 2006-05-30 | Mcgrath Kevin | Peptide activators of VEGF |
| JP4931349B2 (ja) | 2003-01-23 | 2012-05-16 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物 |
| CA2549995C (en) | 2003-12-24 | 2011-11-15 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| JP4553181B2 (ja) | 2004-03-25 | 2010-09-29 | 株式会社サタケ | 残留農薬分析方法 |
| US8209479B2 (en) | 2007-07-18 | 2012-06-26 | Google Inc. | Memory circuit system and method |
| AU2013207423B2 (en) | 2012-01-06 | 2017-10-12 | Gemphire Therapeutics Inc. | Methods of reducing risk of cardiovascular disease |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US20160058751A1 (en) | 2013-03-28 | 2016-03-03 | Cellworks Group, Inc. | Composition and method for treating cancer |
| WO2015018060A1 (en) * | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| MX392182B (es) | 2015-03-13 | 2025-03-21 | Esperion Therapeutics Inc | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| WO2017023165A1 (en) | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
| US20210361618A1 (en) | 2017-02-08 | 2021-11-25 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods for treating or reducing the risk of cardiovascular disease |
| TW201906599A (zh) | 2017-05-11 | 2019-02-16 | 美商珍費爾醫療公司 | 吉卡賓組成物及其使用方法 |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| CN107628975B (zh) * | 2017-09-17 | 2019-10-29 | 贵州医科大学 | 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用 |
| CN109721486A (zh) * | 2017-10-31 | 2019-05-07 | 鲁南制药集团股份有限公司 | 一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法 |
| BR112020016494A2 (pt) | 2018-02-16 | 2020-12-15 | Esperion Therapeutics, Inc. | Formulações de liberação prolongada de ácido bempedoico |
| EP3666750A1 (en) * | 2018-12-10 | 2020-06-17 | Sandoz AG | Crystalline form of bempedoic acid |
| EP3906231A2 (en) | 2018-12-31 | 2021-11-10 | Lupin Limited | Novel salts and polymorphic form of bempedoic acid |
| US12344578B2 (en) | 2019-06-21 | 2025-07-01 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
| EP4069668A1 (en) * | 2019-12-06 | 2022-10-12 | Synthon B.V. | Crystalline forms of sodium salt of bempedoic acid |
| WO2022149161A1 (en) | 2021-01-05 | 2022-07-14 | Dr. Reddy's Laboratories Limited | Process for preparation of bempedoic acid and its intermediates |
-
2020
- 2020-06-19 US US17/620,885 patent/US12344578B2/en active Active
- 2020-06-19 WO PCT/US2020/038622 patent/WO2020257571A1/en not_active Ceased
- 2020-06-19 CN CN202080003148.4A patent/CN112437765A/zh active Pending
- 2020-06-19 AU AU2020296094A patent/AU2020296094B2/en active Active
- 2020-06-19 JP JP2021575994A patent/JP2022536979A/ja not_active Withdrawn
- 2020-06-19 EP EP20737750.8A patent/EP3986859B1/en active Active
- 2020-06-19 WO PCT/US2020/038624 patent/WO2020257573A1/en not_active Ceased
- 2020-06-19 BR BR112021025928A patent/BR112021025928A2/pt active Search and Examination
- 2020-06-19 CA CA3144372A patent/CA3144372A1/en active Pending
- 2020-06-19 KR KR1020257031641A patent/KR20250143358A/ko active Pending
- 2020-06-19 CA CA3144371A patent/CA3144371A1/en active Pending
- 2020-06-19 HU HUE20737750A patent/HUE072061T2/hu unknown
- 2020-06-19 JP JP2021575993A patent/JP2022537049A/ja active Pending
- 2020-06-19 BR BR112021025964A patent/BR112021025964A2/pt not_active Application Discontinuation
- 2020-06-19 EP EP24194322.4A patent/EP4438114A3/en active Pending
- 2020-06-19 MX MX2021015935A patent/MX2021015935A/es unknown
- 2020-06-19 ES ES20737750T patent/ES3032779T3/es active Active
- 2020-06-19 KR KR1020227002107A patent/KR20220024815A/ko not_active Withdrawn
- 2020-06-19 CN CN202080003150.1A patent/CN112437766A/zh active Pending
- 2020-06-19 AU AU2020295503A patent/AU2020295503A1/en not_active Abandoned
- 2020-06-19 MX MX2021015936A patent/MX2021015936A/es unknown
- 2020-06-19 CN CN202211022415.XA patent/CN115429784A/zh active Pending
- 2020-06-19 KR KR1020227002108A patent/KR20220024816A/ko active Pending
- 2020-06-19 EP EP20737751.6A patent/EP3986860A1/en not_active Withdrawn
-
2021
- 2021-01-15 US US17/150,325 patent/US11407705B2/en active Active
- 2021-01-15 US US17/150,321 patent/US20210139405A1/en not_active Abandoned
- 2021-12-12 IL IL288909A patent/IL288909A/en unknown
- 2021-12-14 IL IL288997A patent/IL288997A/en unknown
-
2022
- 2022-01-18 US US17/577,829 patent/US11760714B2/en active Active
- 2022-05-12 US US17/742,728 patent/US11613511B2/en active Active
- 2022-07-19 US US17/867,744 patent/US11987548B2/en active Active
-
2023
- 2023-04-10 US US18/297,846 patent/US11926584B2/en active Active
- 2023-08-16 US US18/450,591 patent/US12404227B2/en active Active
-
2024
- 2024-04-11 US US18/632,996 patent/US20240286987A1/en active Pending
- 2024-05-07 US US18/657,105 patent/US12398087B2/en active Active
- 2024-12-04 JP JP2024211105A patent/JP2025032197A/ja active Pending
-
2025
- 2025-05-06 AU AU2025203232A patent/AU2025203232A1/en active Pending
- 2025-10-19 IL IL324076A patent/IL324076A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020257573A5 (enExample) | ||
| JPWO2022138988A5 (enExample) | ||
| RU2080116C1 (ru) | Средство для лечения болей или воспалений | |
| JP2023036708A5 (enExample) | ||
| JP2024071370A5 (enExample) | ||
| CN1382682A (zh) | 2－(α－羟基戊基)苯甲酸盐及其制法和用途 | |
| CN1970547B (zh) | 非布司他的晶型及其制备方法 | |
| JP2023109937A5 (enExample) | ||
| RU2002113169A (ru) | Измельченная форма (S)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты | |
| RU2015134420A (ru) | Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты | |
| RU2002113450A (ru) | Кристаллическая форма (S)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты | |
| JPWO2020010068A5 (enExample) | ||
| JP2009143954A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| JPWO2022221227A5 (enExample) | ||
| JP2013516475A5 (enExample) | ||
| JP2024045113A5 (enExample) | ||
| RU2002135315A (ru) | Производные хинолонкарбоновой кислоты | |
| JPWO2020051538A5 (enExample) | ||
| RU2007143025A (ru) | Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты | |
| CN101516191A (zh) | Saha的胺碱盐和其多晶型物 | |
| JPWO2023163203A5 (enExample) | ||
| JPWO2019234240A5 (enExample) | ||
| JPWO2019024845A5 (enExample) | ||
| JP2878844B2 (ja) | Ｎ▲ｇ▼−モノメチル−ｌ−アルギニン塩酸塩誘導体および敗血性ショックの治療におけるこれらの使用 | |
| CN102093309B (zh) | 非布司他的晶型及其制备方法 |